Navigation Links
China Medical Technologies Reports Second Fiscal Quarter Financial Results
Date:11/18/2011

ble earnings generated in China which the Company does not intend to permanently reinvest in China.

Net income was RMB33.3 million (US$5.2 million) for 2Q FY2011, compared to net loss of RMB2.9 million for the corresponding period of FY2010. Non-GAAP net income was RMB89.6 million (US$14.0 million) for 2Q FY2011, representing a 36.9% increase from the corresponding period of FY2010. The year-over-year increases were primarily due to the increase in molecular diagnostic system sales and other reasons mentioned above.

Earnings before interest, taxes, depreciation and amortization ("EBITDA") was RMB145.5 million (US$22.8 million) for 2Q FY2011, representing a 35.9% increase from the corresponding period of FY2010. The year-over-year increase was primarily due to the increase in molecular diagnostic system sales.

Adjusted EBITDA was RMB151.4 million (US$23.7 million) for 2Q FY2011, representing a 30.1% increase from the corresponding period of FY2010. The year-over-year increase was primarily due to the increase in molecular diagnostic system sales.

Stock compensation expense for 2Q FY2011 was RMB5.9 million (US$0.9 million), of which RMB0.4 million was allocated to cost of revenues, RMB0.6 million to research and development expenses, RMB0.2 million to sales and marketing expenses and RMB4.7 million to general and administrative expenses. The Company approved the grant of 4,500,000 restricted shares, equivalent to 450,000 ADSs, to directors, officers and certain employees on November 7, 2011. The restricted shares vest at the end of a two-year period.

Amortization of acquired intangible assets for 2Q FY2011 was RMB47.2 million (US$7.4 million) which was all allocated to cost of revenues.

As of September 30, 2011, the Company's cash and cash equivalents were RMB1,316.8 million (US$206.5 million). Net cash generated from operating activities for 2Q FY2011 was RMB79.1 million (US$12.4 million). Net cash used in investing activitie
'/>"/>

SOURCE China Medical Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24

Related medicine technology :

1. HUYA Bioscience Intl Announces Clinical Trial Milestones in China for Promising New Anti-Arrhythmic Compound; Data Supports Desirable Safety Profile
2. HUYA Bioscience Intl Announces World-Class Clinical Advisory Team for New Anti-Arrhythmic Compound Sourced From China
3. HUYA Bioscience Intl Announces First Pre-IND Outcome for a Development Stage Compound Sourced From China - HBI-8000, Promising New Cancer Compound
4. HUYA Bioscience Intl Announces Pre-IND Outcome for HBI-3000 - Promising Anti-Arrhythmia Compound Sourced From China
5. China Sky One Medical, Inc. Announces 26 New Drugs in Clinical Trials
6. RHEI Pharmaceuticals Announces the Initiation of the Final Clinical Study for Approval of Tibozole in China
7. Varian Medical Systems to Exhibit Cancer Treatment and X-ray Imaging Technologies at China Med Exhibition
8. China Sky One Medical, Inc. Achieves Significant Breakthrough in Research for Sudden Cardiac Death (SCD) Early Examination Kit
9. China Animal Welfare Law Under Review While 36,000 Dogs Culled
10. China-Biotics, Inc. Prices $69 Million Public Offering of Common Stock
11. Clifford Chance Advises Pfizer on Conditional Clearance in China of Its Merger with Wyeth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... 2014 UBM Medica US announces that  ... to help oncologists and other clinicians gain a better ... of targeted therapies and immunotherapies, discusses some of the ... Every September, Blood Cancer Awareness Month ... about blood cancers—helping to increase survival rates and improve ...
(Date:9/19/2014)... 19, 2014  Pressure BioSciences, Inc. (OTCQB: PBIO) ... received and approved all parts required to build ... begun to manufacture the new PCT-based instrument system.  ... ready for shipment by mid-October and that additional ... a rate of about one per week thereafter.  ...
(Date:9/19/2014)... , Sept. 19, 2014  Over 200 runners ... Future to Benefit the Radiation Oncology Institute (ROI), hosted ... at Golden Gate Park in San Francisco.  ... Moore , CEO of Radiation Business Solutions, "but ... have raised over $70,000 for the ROI this year. ...
Breaking Medicine Technology:OncoTherapy Network Highlights National Blood Cancer Awareness Month 2OncoTherapy Network Highlights National Blood Cancer Awareness Month 3OncoTherapy Network Highlights National Blood Cancer Awareness Month 4Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 2Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 3Fifth Annual 5K Run for the Future to Benefit the Radiation Oncology Institute Breaks Attendance, Donation Records 2Fifth Annual 5K Run for the Future to Benefit the Radiation Oncology Institute Breaks Attendance, Donation Records 3
... CHADDS FORD, Pa., Oct. 22 Endo Pharmaceuticals (Nasdaq: ... and Company 21st Annual Healthcare Conference on Tuesday, November 2, 2010, ... Endo, will review the company,s products and development programs. ... from Endo,s website at www.endo.com under the investors section. ...
... Pharmaxis (ASX: PXS) today announced significant results of pooled ... III trials of Bronchitol (inhaled mannitol) in people with ... presented for the first time at the North American ... addition, more results from the second trial (CF302) have ...
Cached Medicine Technology:Pharmaxis Announces Positive Combined Phase 3 Cystic Fibrosis Trial Results 2Pharmaxis Announces Positive Combined Phase 3 Cystic Fibrosis Trial Results 3Pharmaxis Announces Positive Combined Phase 3 Cystic Fibrosis Trial Results 4Pharmaxis Announces Positive Combined Phase 3 Cystic Fibrosis Trial Results 5
(Date:9/22/2014)... CA (PRWEB) September 22, 2014 ... course from Winter & Alvin has just been ... excitement throughout the personal development community. The media ... attention of HonestyFirstReviews.com's Tiffany Hendricks prompting an investigative ... topic of great interest for many entrepreneurs and ...
(Date:9/22/2014)... 22, 2014 QueenBeeTickets.com has the largest ... larger with discount Stevie Wonder tickets. The phenomenal singer/songwriter ... Tour,” and 11 cities have been put on the ... , Click Here to view the selection ... , Stevie Wonder ticket sales are bound to be ...
(Date:9/22/2014)... AttorneyOne.com, a recognized authority on law, update the ... on Twix . , Mars Chocolate North America announced ... Stand Up Pouch with specific code date are recalled due ... is that Twix Unwrapped Bites 7 oz. Stand Up Pouch ... writing them on the ingredient label. , In case ...
(Date:9/22/2014)... 2014 The Center for Health ... ERC as one of the NorthCoast 99 ... places to work for top talent. This award recognizes ... maintain great workplaces that support the attraction, retention and ... staffing and workforce, development and training, compensation and rewards, ...
(Date:9/22/2014)... The Ruby Report was launched by the ... Conference in Louisville, Kentucky. This release followed the May ... reception attended by 60 people from the local area. ... gained while conducting her research, what drove her to ... and what she believes companies can do to be ...
Breaking Medicine News(10 mins):Health News:"The Millionaire's Brain" - A Review Examining Winter & Alvin's Training Course Released 2Health News:Discount Stevie Wonder Tickets: QueenBeeTickets.com Delights Customers with Discounted Concert Tickets for Stevie Wonder’s 11-City Tour Set to Kick off in November 2Health News:Mars Chocolate North America Recalls Twix Bites: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:The Center for Health Affairs Named to 2014 NorthCoast 99 List 2Health News:The Center for Health Affairs Named to 2014 NorthCoast 99 List 3Health News:Ruby Report Book Launch Reveals Critical Insights on Gender Intelligence 2
... 10 Caliper Life Sciences, Inc. (Nasdaq: ... at the Cowen and Company 29th Annual Health ... on Tuesday, March 17 at 10:15 a.m. ET. ... will be providing an update on the company,s ...
... Report Finds Public Health Programs At Risk During Economic ... and the Robert Wood Johnson Foundation (RWJF) today released ... received less funding from the federal government than Northeastern ... for disease prevention programs, which can amount to millions ...
... Designed to Optimize Treatment of Patients with Coronary ... Abbott ( NYSE: ABT ) today announced ... a next-generation balloon dilatation catheter with high-pressure capability ... coronary artery disease (CAD) during angioplasty procedures. VOYAGER ...
... 10 Johnson & Johnson will participate in the ... Monday, March 16th at the Boston Marriott Copley Place ... President, Finance and Chief Financial Officer, will represent the ... Time). The webcast will be available to investors and ...
... 10 The Kavli Foundation has announced the appointment ... - only the second president since the Foundation was ... Foundation,s President in late April of this year.Dr. Conn ... acclaimed scientist whose research is focused on plasma physics ...
... in the March issue of the Journal of ... transplantation should be used with caution in patients older ... with high rates of mortality after one year in ... the gold-standard treatment for a variety of end-stage lung ...
Cached Medicine News:Health News:Midwestern and Southern States Receive Least Federal Funding for Disease Prevention 2Health News:Midwestern and Southern States Receive Least Federal Funding for Disease Prevention 3Health News:Midwestern and Southern States Receive Least Federal Funding for Disease Prevention 4Health News:Abbott Launches VOYAGER(TM) NC Coronary Balloon Catheter 2Health News:Abbott Launches VOYAGER(TM) NC Coronary Balloon Catheter 3Health News:Abbott Launches VOYAGER(TM) NC Coronary Balloon Catheter 4Health News:Abbott Launches VOYAGER(TM) NC Coronary Balloon Catheter 5Health News:Dr. Robert W. Conn Named President of The Kavli Foundation 2Health News:Dr. Robert W. Conn Named President of The Kavli Foundation 3Health News:Dr. Robert W. Conn Named President of The Kavli Foundation 4Health News:Journal of American College of Surgeons finds lung transplantation should be used in older patients 2
... enzyme immunoassay kit for the quantitative ... in serum. Enzyme immunoassay (EIA) permits ... protein hormones in body fluids and ... and specific assay. This enzyme immunoassay ...
SHIONORIA BNP,is a reagent used in the measurement of blood BNP. The blood BNP test allows accurate estimation of coronary functions....
... immunosorbent assay method for the semi-quantitative ... myeloperoxidase in human serum. The results ... used as an aid in the ... conditions associated with elevated anti-neutrophil cytoplasmic ...
... The determination of Ang II ... monitoring the pharmacological effect and ... of angiotensin converting enzyme inhibitors ... receptor antagonists as well as ...
Medicine Products: